This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Karo Pharma Past Earnings Performance

Past criteria checks 0/6

Key information

-46.51%

Earnings growth rate

-52.88%

EPS growth rate

Pharmaceuticals Industry Growth	5.95%
Revenue growth rate	29.81%
Return on equity	-2.30%
Net Margin	-5.48%
Last Earnings Update	30 Jun 2022

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Karo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:KARB.F Revenue, expenses and earnings (SEK Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 22	3,466	-190	1,935	0
31 Mar 22	3,231	-141	1,745	0
31 Dec 21	2,961	-17	1,513	0
30 Sep 21	2,921	63	1,338	0
30 Jun 21	2,861	2	1,404	0
31 Mar 21	2,802	49	1,303	0
31 Dec 20	2,883	82	1,351	0
30 Sep 20	2,811	86	1,181	0
30 Jun 20	2,575	87	1,016	0
31 Mar 20	2,274	55	842	0
31 Dec 19	1,901	9	681	0
30 Sep 19	1,715	60	673	0
30 Jun 19	1,667	117	611	0
31 Mar 19	1,769	650	581	0
31 Dec 18	1,615	657	521	1
30 Sep 18	1,391	595	445	2
30 Jun 18	1,132	551	369	2
31 Mar 18	785	40	288	3
31 Dec 17	658	15	242	4
30 Sep 17	515	141	178	3
30 Jun 17	463	133	158	5
31 Mar 17	404	114	153	5
31 Dec 16	347	96	141	5
30 Sep 16	308	-20	130	10
30 Jun 16	232	-41	110	13
31 Mar 16	151	-60	77	29
31 Dec 15	69	-78	54	35

Quality Earnings: KARB.F is currently unprofitable.

Growing Profit Margin: KARB.F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KARB.F is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.

Accelerating Growth: Unable to compare KARB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KARB.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.4%).

Return on Equity

High ROE: KARB.F has a negative Return on Equity (-2.3%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/11/08 20:04
End of Day Share Price	2022/08/11 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Karo Pharma AB (publ) is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Camilla Oxhamre	Carnegie Investment Bank AB
Olle Sjölin	Nordea Markets
Peter Abelin	Redeye